General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Castle Biosciences in its US$74 Million Public Offering of Common Stock

June 29, 2020
A capital markets team represented the life sciences company in the offering.

Castle Biosciences, Inc., has announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a price to the public of US$37.00 per share. The gross proceeds to Castle Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be US$74.0 million. In addition, Castle Biosciences has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock at the offering price, less the underwriting discounts and commissions. 

Latham & Watkins LLP represents Castle Biosciences, Inc. in the public offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Anthony Gostanian and Kiara Vaughn. 
 

    Related Capabilities